#Scinai Immunotherapeutics #Israel #Jerusalem #revenue growth #CDMO Services

Scinai Immunotherapeutics Reports Strong Financial Performance

In the latest update released on November 5, 2026, Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced impressive financial results for the first nine months of the year 2026. The biopharmaceutical company, which specializes in contract development and manufacturing operations (CDMO), reported a staggering 167% increase in revenue, reaching $2.8 million compared to $1.05 million during the same period in 2025. This growth is primarily attributed to the expansion of its CDMO business and the integration of Yavne operations acquired earlier this year.

Expanded U.S. Customer Agreements

One of the significant milestones for Scinai during this reporting period is the establishment of an expanded U.S. customer agreement with its wholly-owned CDMO subsidiary, Scinai Biopharma Services Ltd. The agreement, finalized in October 2026, includes approximately $5.1 million in committed base service fees. This setup enhances an existing partnership into a comprehensive clinical manufacturing arrangement, further solidifying Scinai's foothold in the competitive biopharmaceutical landscape.

As of November 4, 2026, the company's committed customer orders have soared to about $8.32 million, representing an over 330% increase from the $1.9 million recorded at the end of 2025. This figure reflects not just the commitments for the current year but also authorized work slated for completion in 2027. It is important to note that committed customer orders measure authorized services without guaranteeing immediate revenue recognition.

Financial Health and Operational Enhancements

Scinai’s liquidity was bolstered by financing transactions that generated approximately $5.3 million in combined net proceeds. With bank balances reported at around $8.1 million as of late October 2026, the company is well-positioned to support its ongoing CDMO operations well into late 2027. CEO Amir Reichman emphasized the importance of customer delivery and cash generation, both of which are trending upward compared to the previous year.

Expanding its service capabilities is a key focus for Scinai, especially as clinical manufacturing is expected to commence under the expanded U.S. program starting January 2027. This initiative not only aims to enhance the company's revenue but also seeks to build a reliable operational framework that can attract repeat business.

Strategic Focus on Sustainable Profitability

The commitment to sustainable profitability remains central to Scinai's operational strategy. Amid the backdrop of growing customer engagements, the company aims to convert these commitments into tangible revenue, encompassing growth in cash flow and improved operational results. Reichman stated that Scinai's focus is now on navigating through delivery milestones while also managing costs effectively to maximize profitability.

Therapeutic Development and Future Outlook

Beyond financial metrics, Scinai's commitment to advancing its therapeutic development platform, particularly its NanoAb innovations, remains strong. Collaborations with prestigious institutions aim to enhance their therapeutic pipeline through cutting-edge research initiatives. While the company has decided not to pursue renewals related to prior agreements, it continues to explore other avenues for development and funding to advance its pipeline efficiently.

In summary, the results from the first nine months of 2026 highlight Scinai Immunotherapeutics’ exceptional growth trajectory, driven by strategic expansions in its CDMO sector and focused operational improvements. As they look to the future, the commitment to navigating the challenges and opportunities in clinical manufacturing and therapy development is expected to reinforce their position in the biopharmaceutical industry.